MedPath

NSAID

Generic Name
NSAID
Clinical Trials
Related News

Novel LION Trial Combines Anti-inflammatory Drug with Immunotherapy to Combat Advanced Cancers

• The groundbreaking LION trial investigates the combination of celecoxib with immunotherapy to treat advanced triple-negative breast cancer, non-small cell lung cancer, and renal cell carcinoma. • Led by The Christie NHS Foundation Trust, the trial aims to recruit 89 patients across six UK sites, with 11 patients already enrolled in this innovative treatment approach. • The study, funded by The Christie Charity and The Jon Moulton Charity Trust, explores whether reducing inflammation can enhance immunotherapy's effectiveness in fighting cancer.

ACP Issues New Treatment Guidelines for Episodic Migraine Management

• The American College of Physicians has released new guidelines for treating episodic migraine, recommending a three-tiered approach based on systematic review of nine medication classes. • First-line treatments include beta-blockers (metoprolol/propranolol), valproate, venlafaxine, or amitriptyline, while CGRP antagonists and antibodies are recommended as second-line options. • The guidelines emphasize cost considerations and patient preferences, noting significant price variations between treatments, from $67 for amitriptyline to over $22,000 for some CGRP antagonists.

FDA Approves Axsome's Symbravo (Meloxicam and Rizatriptan) for Acute Migraine Treatment

• The FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults, offering a novel multi-mechanistic approach. • Clinical trials demonstrated that Symbravo can rapidly eliminate migraine pain and allow patients to return to normal functioning with a single dose. • Studies showed a statistically significant percentage of patients achieved pain freedom and were free from their most bothersome symptom within two hours of dosing versus placebo. • Axsome Therapeutics anticipates Symbravo will be commercially available in the U.S. in approximately four months, providing a new option for migraine sufferers.

FDA Approves Journavx, a Novel Non-Opioid Painkiller, Offering New Hope for Acute Pain Management

• The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids. • Journavx works by selectively blocking pain signals in the peripheral nervous system, reducing pain without the addictive potential and severe side effects associated with opioids. • Clinical trials demonstrated Journavx's effectiveness in reducing pain after surgeries, with a safety profile comparable to placebo, though it didn't outperform opioid-acetaminophen combinations. • Priced at $15.50 per pill, Journavx faces challenges in accessibility due to its higher cost compared to generic opioids, but it represents a significant step in combating the opioid crisis.

Natera's Signatera Guides Personalized Treatment in Phase III Colon Cancer Trial

• Natera's SAGITTARIUS trial uses Signatera to personalize colon cancer treatment strategies, marking a shift from the one-size-fits-all approach. • The trial randomizes Signatera-positive patients to genotype-guided therapy or standard chemotherapy, exploring immunotherapy and targeted agents. • Signatera-negative patients in the study will receive physician's choice of treatment, including observation or single-agent capecitabine. • The SAGITTARIUS project, funded by the EU, involves 9 partners across Europe and 26 clinical centers, aiming for cost-effective, tailored treatments.

NTC's NTC014 Demonstrates Efficacy in Phase II Trial for Bacterial Conjunctivitis

• NTC014, a combination of quinolone antibiotic and NSAID eye drops, shows promise in treating bacterial conjunctivitis in adults. • The Phase II MIRAKLE study demonstrated NTC014's non-inferiority to antibiotic-only treatment in microbiological eradication. • NTC014 exhibited efficacy against pathogens with intermediate or resistant to the tested quinolone antibiotic. • NTC aims to finalize commercial partnerships for NTC014 in most countries by the end of 2025, with potential for surgical applications.

Induction of Cure in Early Arthritis (I CEA) Trial: Evaluating Treatment Strategies for Undifferentiated Arthritis

• The I CEA trial is a multicenter, randomized clinical trial evaluating three treatment strategies for early undifferentiated arthritis. • The primary outcome is the change in disease activity score (DAS) at 3 months, with a 9-month observational follow-up period. • Treatment arms include symptom relief with NSAIDs, methotrexate (MTX), or baricitinib, each combined with glucocorticoids. • The trial aims to identify the best early treatment strategy to reduce disease activity and improve outcomes in patients with early arthritis.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy